In:
International Journal of Dermatology, Wiley
Abstract:
Biological therapy dose modification is a common practice in the long‐term treatment of plaque psoriasis. Objective The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC‐DR) strategy and assess its safety and cost implications. Methods A retrospective, observational, multicenter cohort study was conducted in patients with plaque psoriasis treated with secukinumab and up to 2 years of follow‐up. Results In 63/347 patients with an initial standard dose regimen, SEC‐DR was tried at any moment in 18.2% of them after sustained response. In 51 patients, the interval between administrations was increased while in 12 patients, monthly dose was reduced to 150 mg. Successful SEC‐DR was achieved in 77.8% of the patients, with sustained PASI response to the end of the study. Survival of secukinumab treatment and safety profile were not compromised by DR. The use of DR saved 33% of the cost, including failures in which standard treatment was resumed. Limitations The proper of the study designed and the arbitrary definition of “DR success.” Conclusion Off‐label SEC‐DR strategy was used in patients with sustained response to standard dose regimen; this strategy showed long‐term efficacy without compromising treatment survival or worsening the safety profile while also being cost saving.
Type of Medium:
Online Resource
ISSN:
0011-9059
,
1365-4632
Language:
English
Publisher:
Wiley
Publication Date:
2024
detail.hit.zdb_id:
2020365-2
